Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (389 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-02-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: kidneytransplantsubjectdonortolerability
  Phrases that lowered it: evaluate theweeksat screeningsafety andcount
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Minimum age: 21 (lowers risk) · Who can join
• Phase: 2 (raises risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Responsible party: not given (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Maximum age: 70 (lowers risk) · Who can join
• Sponsor's past trials: 0 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study to Evaluate the Effect of ASP8597 in Adult Kidney Transplant Patients NCT01442337 · started 2011 · scored riskier than 29% of active trials terminated
• Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Renal Transplantation (The ONE Study ) NCT02244801 · started 2015 · scored riskier than 87% of active trials completed
• I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation NCT00802347 · started 2008 · scored riskier than 99% of active trials completed
• A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients NCT01163799 · started 2010 · scored riskier than 53% of active trials terminated
• A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation NCT01279538 · started 2010 · scored riskier than 76% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.